Alzeca Biosciences, Inc. is a Houston-based company that specializes in the development of advanced imaging agents for the early detection of neurodegenerative diseases, particularly Alzheimer's Disease. Their innovative agents, based on MRI and CT scanning technologies, offer significant advantages over current PET scan methods, including lower cost and broader availability worldwide.
With a focus on early diagnosis, Alzeca aims to provide valuable prognostic information to families and enable preemptive treatment when the disease is more manageable. Supported by private investors and grants from renowned organizations, Alzeca is led by a team of experts in diagnostic imaging innovation and clinical neuroscience, backed by over 25 years of experience in drug development.
Generated from the website